273 related articles for article (PubMed ID: 36880750)
41. Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial.
Zhang G; Yuan J; Pan C; Xu Q; Cui X; Zhang J; Liu M; Song Z; Wu L; Wu D; Luo H; Hu Y; Jiao S; Yang B
EBioMedicine; 2023 Apr; 90():104515. PubMed ID: 36921563
[TBL] [Abstract][Full Text] [Related]
42. Clinicopathological correlation of PD-L1 and TET1 expression with tumor-infiltrating lymphocytes in non-small cell lung cancer.
Ahn H; Lee HJ; Lee JH; Cho HD; Oh MH; Son JW; Jang SH
Pathol Res Pract; 2020 Nov; 216(11):153188. PubMed ID: 32919305
[TBL] [Abstract][Full Text] [Related]
43. Tumor regression rate, PD-L1 expression, pembrolizumab/nab-paclitaxel-based regimens, squamous cell carcinoma, and comorbidities were independently associated with efficacy of neoadjuvant chemoimmunotherapy in non-small cell lung cancer.
Hu X; Hu C; Liu X; Ma F; Xie J; Zhong P; Tang C; Fan D; Gao Y; Feng X; Ding M; Li D; Liu C
Front Oncol; 2022; 12():1057646. PubMed ID: 36776373
[TBL] [Abstract][Full Text] [Related]
44. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
45. Utility of
Zhuang F; Haoran E; Huang J; Wu J; Xu L; Zhang L; Li Q; Li C; Zhao Y; Yang M; Ma M; She Y; Chen H; Luo Q; Zhao D; Chen C
Lung Cancer; 2023 Apr; 178():20-27. PubMed ID: 36764154
[TBL] [Abstract][Full Text] [Related]
46. PD-L1 expression, CD8+ and CD4+ lymphocyte rate are predictive of pathological complete response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic esophagus.
Fassan M; Cavallin F; Guzzardo V; Kotsafti A; Scarpa M; Cagol M; Chiarion-Sileni V; Maria Saadeh L; Alfieri R; Castagliuolo I; Rugge M; Castoro C; Scarpa M
Cancer Med; 2019 Oct; 8(13):6036-6048. PubMed ID: 31429521
[TBL] [Abstract][Full Text] [Related]
47. Smoking History Predicts High Presence of TILs and Efficacy of PD-1 Blockade in PD-L1 Expression-negative Non-small Cell Lung Cancer Patients.
Shimoda Y; Yoshida T; Shirasawa M; Mizuno T; Jo H; Matsumoto Y; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Yatabe Y; Ohe Y; Motoi N
Anticancer Res; 2021 Nov; 41(11):5739-5747. PubMed ID: 34732447
[TBL] [Abstract][Full Text] [Related]
48. Neoadjuvant immunotherapy or chemoimmunotherapy in non-small cell lung cancer: a systematic review and meta-analysis.
Jiang J; Wang Y; Gao Y; Sugimura H; Minervini F; Uchino J; Halmos B; Yendamuri S; Velotta JB; Li M
Transl Lung Cancer Res; 2022 Feb; 11(2):277-294. PubMed ID: 35280319
[TBL] [Abstract][Full Text] [Related]
49. Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer.
Liu H; Zhang T; Ye J; Li H; Huang J; Li X; Wu B; Huang X; Hou J
Cancer Immunol Immunother; 2012 Oct; 61(10):1849-56. PubMed ID: 22456757
[TBL] [Abstract][Full Text] [Related]
50. Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer.
Zhang L; Chen Y; Wang H; Xu Z; Wang Y; Li S; Liu J; Chen Y; Luo H; Wu L; Yang Y; Zhang H; Peng H
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34140315
[TBL] [Abstract][Full Text] [Related]
51. Platinum-based neoadjuvant chemotherapy upregulates STING/IFN pathway expression and promotes TILs infiltration in NSCLC.
Gao H; Zhang X; Ren M; Jiang A; Liu N; Wang J; Zheng X; Liang X; Ruan Z; Tian T; Fu X; Yao Y
Front Oncol; 2024; 14():1346225. PubMed ID: 38425343
[TBL] [Abstract][Full Text] [Related]
52. [Experience of Thoracotomy and Robot-assisted Bronchial Sleeve Resection
after Neoadjuvant Chemoimmunotherapy for Local Advanced Central Lung Cancer].
Liu X; Sun T; Hong T; Yuan Y; Zhang H
Zhongguo Fei Ai Za Zhi; 2022 Feb; 25(2):71-77. PubMed ID: 35224959
[TBL] [Abstract][Full Text] [Related]
53. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME
Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075
[TBL] [Abstract][Full Text] [Related]
54. Spatial and temporal heterogeneity of tumor immune microenvironment between primary tumor and brain metastases in NSCLC.
Liu JS; Cai YX; He YZ; Xu J; Tian SF; Li ZQ
BMC Cancer; 2024 Jan; 24(1):123. PubMed ID: 38267913
[TBL] [Abstract][Full Text] [Related]
55. Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
Gennen K; Käsmann L; Taugner J; Eze C; Karin M; Roengvoraphoj O; Neumann J; Tufman A; Orth M; Reu S; Belka C; Manapov F
Radiat Oncol; 2020 Jan; 15(1):5. PubMed ID: 31898519
[TBL] [Abstract][Full Text] [Related]
56. Immune Microenvironment Differences Between Squamous and Non-squamous Non-small-cell Lung Cancer and Their Influence on the Prognosis.
Meng X; Gao Y; Yang L; Jing H; Teng F; Huang Z; Xing L
Clin Lung Cancer; 2019 Jan; 20(1):48-58. PubMed ID: 30341017
[TBL] [Abstract][Full Text] [Related]
57. Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer.
Kim CG; Kim G; Kim KH; Park S; Shin S; Yeo D; Shim HS; Yoon HI; Park SY; Ha SJ; Kim HR
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34907028
[TBL] [Abstract][Full Text] [Related]
58. Pathological complete response to neoadjuvant tislelizumab plus chemotherapy in stage IIIB small cell lung cancer: A case report and literature review.
Zhou N; Chen Y; Huang Q; Jiang L; Liao H; Gou H; Lu Y; Che G; Zhang Y
Front Immunol; 2023; 14():1111325. PubMed ID: 36911701
[TBL] [Abstract][Full Text] [Related]
59. Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC.
Shirasawa M; Yoshida T; Shimoda Y; Takayanagi D; Shiraishi K; Kubo T; Mitani S; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Ichikawa H; Kohno T; Yamamoto N; Matsumoto S; Goto K; Watanabe SI; Ohe Y; Motoi N
J Thorac Oncol; 2021 Dec; 16(12):2078-2090. PubMed ID: 34419685
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+ and FOXP3+ immune cells in HER2-positive breast cancer treated with neoadjuvant therapies.
Zhao J; Meisel J; Guo Y; Nahta R; Hsieh KL; Peng L; Wei Z; O'Regan R; Li X
Breast Cancer Res Treat; 2020 Oct; 183(3):599-606. PubMed ID: 32715443
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]